Compare Gilead Sciences, Inc. (GILD) vs Vital Farms Inc (VITL) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Gilead Sciences, Inc. vs Vital Farms Inc — how do they compare? Gilead Sciences, Inc. trades at $147.01 (market cap $182.40B), while Vital Farms Inc trades at $9.45 (market cap $405.27M). The key difference: Gilead Sciences, Inc. is far larger — about 450.1× Vital Farms Inc's market cap, and Gilead Sciences, Inc. pays a 2.23% dividend while Vital Farms Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Gilead Sciences, Inc. for 111 Days and Vital Farms Inc for 14 Days on average.
| GILD | VITL | |
|---|---|---|
Market Cap | $182.40B | $405.27M |
Volume | 4,469,821 | 1,810,837 |
Sector | Health | Consumer Staples |
52-Week High | $155.80 | $43.68 |
52-Week Low | $116.74 | $8.28 |
Typical Hold Time | 111 Days | 14 Days |
Enterprise Value | $205.46B | $492.28M |
Dividend Yield | 2.23% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Gilead Sciences (GILD) trades at $146.85, up 1.82% with bullish technical signals and strong analyst support. Recent earnings beat expectations in three consecutive quarters, though Q2 showed a significant loss. The company maintains robust operating cash flow of $10.02B (2025) and expanded HIV prevention access through a major PAHO partnership. Valuation metrics show a P/E of 17.84 and P/S of 6.02, with revenue growth from $29.44B (2025) to projected $30.5B (2026).
Outlook remains positive with 65% analyst buy ratings and $151.57 consensus target, though risks include negative net income margin (-10.64%) and high debt levels. The stock offers dividend income ($0.82 upcoming) and pipeline catalysts in oncology/HIV, but investors should monitor earnings volatility and competitive pressures in biopharma.
Vital Farms (VITL) trades at $9.24, down 1.7% on the day, reflecting ongoing pressure from weak earnings and industry headwinds. The stock shows a bearish technical trend with key support at $9.00, while fundamentals reveal a sharp decline in profitability with a net margin of just 0.02% in 2026. Recent news highlights strategic review discussions and institutional acquisitions, yet negative cash flow and pricing challenges in the egg market weigh on investor confidence.
The outlook remains cautious with significant execution risks amid industry oversupply, though analyst consensus suggests upside potential to a $13.11 price target. Investment opportunity hinges on a successful strategic review and margin recovery, but risks include sustained cash burn and competitive pressures that could limit near-term gains.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Gilead Sciences, Inc.
Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. The acquisitions of Corus Pharma, Myogen, CV Therapeutics, Arresto Biosciences, and Calistoga have broadened this focus to include pulmonary and cardiovascular diseases and cancer. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of combination drug Harvoni, and the Kite, Forty Seven, and Immunomedics acquisitions boost Gilead's exposure to cell therapy and noncell therapy in oncology.
Read more on GILD →About Vital Farms Inc
Vital Farms is a leading provider of ethically produced, pasture-raised eggs and butter in the United States. Operating as a Public Benefit Corporation, it manages a network of over 650 family farms to deliver high-welfare food products. It leverages a scalable 'asset-light' partnership model that prioritizes transparency and animal welfare to meet the growing consumer demand for clean-label and sustainable food sources.
Read more on VITL →
